Spruce Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Spruce Biosciences (SPRB).

Price Target Range — 10 Quarters

Analyst Consensus — 11 Analysts

2S.Buy

7Buy

2Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$157Upside to Avg. PT+191.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$123→$104
Aug 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$150→$144
Jul 13, 2026	B. Riley Securities	Madison El-Saadi	Initiate	Buy	$160
Jun 16, 2026	Guggenheim	Debjit Chattopadhyay	Initiate	Buy	$123
Jun 9, 2026	Jones Trading	Catherine Novack	Initiate	Buy	$135
Jun 1, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$200→$150
May 14, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$170→$150
Apr 27, 2026	Craig-Hallum	Albert Lowe	Initiate	Buy	$140
Mar 10, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$180→$170
Mar 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$200
Feb 19, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$220→$200
Dec 23, 2025	Oppenheimer	Leland Gershell	Initiate	Outperform	$283
Dec 22, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Assumes	Buy	$220
Dec 3, 2025	Leerink Partners	Joseph Schwartz	Upgrade	Market Perform→Outperform	$160
Nov 11, 2025	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$254→$259
Oct 28, 2025	JMP Securities	Jonathan Wolleben	Upgrade	Market Perform→Market Outperform	$254
Oct 21, 2025	Leerink Partners	Joseph Schwartz	PT Raise	Market Perform	$10→$160
Apr 16, 2025	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$2→$1
Dec 16, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	—
Dec 12, 2024	Guggenheim	Evan Wang	Maintained	Neutral	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.

Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.

Benzinga Newsdesk

PRO
Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135

Jones Trading analyst Catherine Novack initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $135.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $200 to $150.

Benzinga Newsdesk

Spruce Biosciences Inc

Spruce Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

PRO
Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135

PRO
HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150

People Also Watch

People Also Watch

Spruce Biosciences Inc

Spruce Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PROCitizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PROB. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PROGuggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

PROJones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135

PROHC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

PRO
Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135

PRO
HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150